{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:12:05Z","timestamp":1791299525755,"version":"4.1.0"},"reference-count":26,"publisher":"American Association for Cancer Research (AACR)","issue":"5","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2009,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Hepatocellular carcinoma (HCC) has a high mortality in East Asia and Sub-Saharan Africa, two regions where the main etiologic factors are chronic infections with hepatitis B virus and dietary exposure to aflatoxin. A single base substitution at the third nucleotide of codon 249 of TP53 (R249S) is common in HCC in these regions and has been associated with aflatoxin-DNA adducts. To determine whether R249S may be detected in plasma DNA before HCC diagnosis, we conducted a case-control study nested in a cohort of adult chronic hepatitis B virus carriers from Qidong County, People's Republic of China. Of the 234 plasma specimens that yielded adequate DNA, only 2 (0.9%) were positive for R249S by restriction fragment length polymorphisms, and both of them were controls. Of the 249 subjects tested for aflatoxin-albumin adducts, 168 (67%) were positive, with equal distribution between cases and controls. Aflatoxin-albumin adduct levels were low in the study, suggesting an overall low ongoing exposure to aflatoxin in this cohort. The R249S mutation was detected in 11 of 18 (61%) available tumor tissues. To assess whether low levels of mutant DNA were detectable in pre-diagnosis plasma, 14 plasma specimens from these patients were analyzed by short oligonucleotide mass analysis. Nine of them (64%) were found to be positive. Overall, these results suggest that HCC containing R249S can occur in the absence of significant recent exposure to aflatoxins. The use of short oligonucleotide mass analysis in the context of low ongoing aflatoxin exposure may allow the detection of R249S in plasma several months ahead of clinical diagnosis. (Cancer Epidemiol Biomarkers Prev 2009;18(5):1638\u201343)<\/jats:p>","DOI":"10.1158\/1055-9965.epi-08-1102","type":"journal-article","created":{"date-parts":[[2009,5,7]],"date-time":"2009-05-07T07:27:37Z","timestamp":1241681257000},"page":"1638-1643","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["<i>TP53 R249S<\/i> Mutations, Exposure to Aflatoxin, and Occurrence of Hepatocellular Carcinoma in a Cohort of Chronic Hepatitis B Virus Carriers from Qidong, China"],"prefix":"10.1158","volume":"18","author":[{"given":"Katarzyna","family":"Szyman\u0303ska","sequence":"first","affiliation":[{"name":"1IARC, Lyon, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Guo","family":"Chen","sequence":"additional","affiliation":[{"name":"2Qidong Liver Cancer Institute and Qidong Cancer Registry, Department of Epidemiology, QDLCI, Jiangsu, P.R. China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Cui","sequence":"additional","affiliation":[{"name":"3Office of Health Assessment and Epidemiology, Los Angeles County Department of Public Health, Los Angeles, California;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun Yun","family":"Gong","sequence":"additional","affiliation":[{"name":"4Molecular Epidemiology Unit, Centre for Epidemiology and Biostatistics, LIGHT Laboratories, University of Leeds, Leeds, United Kingdom; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul Craig","family":"Turner","sequence":"additional","affiliation":[{"name":"4Molecular Epidemiology Unit, Centre for Epidemiology and Biostatistics, LIGHT Laboratories, University of Leeds, Leeds, United Kingdom; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ste\u0301phanie","family":"Villar","sequence":"additional","affiliation":[{"name":"1IARC, Lyon, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher Paul","family":"Wild","sequence":"additional","affiliation":[{"name":"4Molecular Epidemiology Unit, Centre for Epidemiology and Biostatistics, LIGHT Laboratories, University of Leeds, Leeds, United Kingdom; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald Maxwell","family":"Parkin","sequence":"additional","affiliation":[{"name":"5Clinical Trial Service Unit and Epidemiological Studies Unit, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Hainaut","sequence":"additional","affiliation":[{"name":"1IARC, Lyon, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2009,5,7]]},"reference":[{"key":"2022061000213242200_BIB1","doi-asserted-by":"crossref","unstructured":"Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol\u20082001;2:533\u201343.","DOI":"10.1016\/S1470-2045(01)00486-7"},{"key":"2022061000213242200_BIB2","doi-asserted-by":"crossref","unstructured":"Ming L, Thorgeirsson SS, Gail MH, et al. Dominant role of hepatitis B virus and cofactor role of aflatoxin in hepatocarcinogenesis in Qidong, China. Hepatology\u20082002;36:1214\u201320.","DOI":"10.1053\/jhep.2002.36366"},{"key":"2022061000213242200_BIB3","unstructured":"Wang JS, Qian GS, Zarba A, et al. Temporal patterns of aflatoxin-albumin adducts in hepatitis B surface antigen-positive and antigen-negative residents of Daxin, Qidong County, People's Republic of China. Cancer Epidemiol Biomarkers Prev\u20081996;5:253\u201361."},{"key":"2022061000213242200_BIB4","doi-asserted-by":"crossref","unstructured":"Montesano R, Hainaut P, Wild CP. Hepatocellular carcinoma: from gene to public health. J Natl Cancer Inst\u20081997;89:1844\u201351.","DOI":"10.1093\/jnci\/89.24.1844"},{"key":"2022061000213242200_BIB5","doi-asserted-by":"crossref","unstructured":"Wild CP, Turner PC. The toxicology of aflatoxins as a basis for public health decisions. Mutagenesis\u20082002;17:471\u201381.","DOI":"10.1093\/mutage\/17.6.471"},{"key":"2022061000213242200_BIB6","doi-asserted-by":"crossref","unstructured":"Smela ME, Hamm ML, Henderson PT, Harris CM, Harris TM, Essigmann JM. The aflatoxin B1 formamidopyrimidine adduct plays a major role in causing the types of mutations observed in human hepatocellular carcinoma. Proc Natl Acad Sci U S A\u20082002;99:6655\u201360.","DOI":"10.1073\/pnas.102167699"},{"key":"2022061000213242200_BIB7","unstructured":"Stern MC, Umbach DM, Yu MC, London SJ, Zhang ZQ, Taylor JA. Hepatitis B, aflatoxin B1, and p53 codon 249 mutation in hepatocellular carcinomas from Guangxi, People's Republic of China, and a meta-analysis of existing studies. Cancer Epidemiol Biomarkers Prev\u20082001;10:617\u201325."},{"key":"2022061000213242200_BIB8","doi-asserted-by":"crossref","unstructured":"Hsieh DP, Atkinson DN. Recent aflatoxin exposure and mutation at codon 249 of the human p53 gene: lack of association. Food Addit Contam\u20081995;12:421\u20134.","DOI":"10.1080\/02652039509374324"},{"key":"2022061000213242200_BIB9","doi-asserted-by":"crossref","unstructured":"Jackson PE, Kuang SY, Wang JB, et al. Prospective detection of codon 249 mutations in plasma of hepatocellular carcinoma patients. Carcinogenesis\u20082003;24:1657\u201363.","DOI":"10.1093\/carcin\/bgg101"},{"key":"2022061000213242200_BIB10","doi-asserted-by":"crossref","unstructured":"Kirk GD, Lesi OA, Mendy M, et al. 249(ser) TP53 mutation in plasma DNA, hepatitis B viral infection, and risk of hepatocellular carcinoma. Oncogene\u20082005;24:5858\u201367.","DOI":"10.1038\/sj.onc.1208732"},{"key":"2022061000213242200_BIB11","doi-asserted-by":"crossref","unstructured":"Chen JG, Parkin DM, Chen QG, et al. Screening for liver cancer: results of a randomised controlled trial in Qidong, China. J Med Screen\u20082003;10:204\u20139.","DOI":"10.1258\/096914103771773320"},{"key":"2022061000213242200_BIB12","doi-asserted-by":"crossref","unstructured":"Szymanska K, Lesi OA, Kirk GD, et al. Ser-249TP53 mutation in tumour and plasma DNA of hepatocellular carcinoma patients from a high incidence area in the Gambia, West Africa. Int J Cancer\u20082004;110:374\u20139.","DOI":"10.1002\/ijc.20103"},{"key":"2022061000213242200_BIB13","doi-asserted-by":"crossref","unstructured":"Laken SJ, Jackson PE, Kinzler KW, et al. Genotyping by mass spectrometric analysis of short DNA fragments. Nat Biotechnol\u20081998;16:1352\u20136.","DOI":"10.1038\/4333"},{"key":"2022061000213242200_BIB14","unstructured":"Hamelin R, Jego N, Laurent-Puig P, Vidaud M, Thomas G. Efficient screening of p53 mutations by denaturing gradient gel electrophoresis in colorectal tumors. Oncogene\u20081993;8:2213\u201320."},{"key":"2022061000213242200_BIB15","doi-asserted-by":"crossref","unstructured":"Taniere P, Martel-Planche G, Saurin JC, et al. TP53 mutations, amplification of P63 and expression of cell cycle proteins in squamous cell carcinoma of the oesophagus from a low incidence area in Western Europe. Br J Cancer\u20082001;85:721\u20136.","DOI":"10.1054\/bjoc.2001.1990"},{"key":"2022061000213242200_BIB16","unstructured":"Wild CP, Jiang YZ, Sabbioni G, Chapot B, Montesano R. Evaluation of methods for quantitation of aflatoxin-albumin adducts and their application to human exposure assessment. Cancer Res\u20081990;50:245\u201351."},{"key":"2022061000213242200_BIB17","unstructured":"Wang CN, Liang Z, Wei P, et al. Changes in dietary patterns and certain nutrition-related diseases in urban and rural residents of Jiangsu Province, China, during the 1990s. Biomed Environ Sci\u20082002;15:271\u20136."},{"key":"2022061000213242200_BIB18","unstructured":"Qian GS, Ross RK, Yu MC, et al. A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People's Republic of China. Cancer Epidemiol Biomarkers Prev\u20081994;3:3\u201310."},{"key":"2022061000213242200_BIB19","doi-asserted-by":"crossref","unstructured":"Wang LY, Hatch M, Chen CJ, et al. Aflatoxin exposure and risk of hepatocellular carcinoma in Taiwan. Int J Cancer\u20081996;67:620\u20135.","DOI":"10.1002\/(SICI)1097-0215(19960904)67:5<620::AID-IJC5>3.0.CO;2-W"},{"key":"2022061000213242200_BIB20","unstructured":"Jackson PE, Qian GS, Friesen MD, et al. Specific p53 mutations detected in plasma and tumors of hepatocellular carcinoma patients by electrospray ionization mass spectrometry. Cancer Res\u20082001;61:33\u20135."},{"key":"2022061000213242200_BIB21","doi-asserted-by":"crossref","unstructured":"Hsia CC, Nakashima Y, Thorgeirsson SS, et al. Correlation of immunohistochemical staining and mutations of p53 in human hepatocellular carcinoma. Oncol Rep\u20082000;7:353\u20136.","DOI":"10.3892\/or.7.2.353"},{"key":"2022061000213242200_BIB22","doi-asserted-by":"crossref","unstructured":"Hsu IC, Metcalf RA, Sun T, Welsh JA, Wang NJ, Harris CC. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature\u20081991;350:427\u20138.","DOI":"10.1038\/350427a0"},{"key":"2022061000213242200_BIB23","unstructured":"Scorsone KA, Zhou YZ, Butel JS, Slagle BL. p53 mutations cluster at codon 249 in hepatitis B virus-positive hepatocellular carcinomas from China. Cancer Res\u20081992;52:1635\u20138."},{"key":"2022061000213242200_BIB24","doi-asserted-by":"crossref","unstructured":"Kirk GD, Camus-Randon AM, Mendy M, et al. Ser-249 p53 mutations in plasma DNA of patients with hepatocellular carcinoma from The Gambia. J Natl Cancer Inst\u20082000;92:148\u201353.","DOI":"10.1093\/jnci\/92.2.148"},{"key":"2022061000213242200_BIB25","doi-asserted-by":"crossref","unstructured":"Huang XH, Sun LH, Lu DD, et al. Codon 249 mutation in exon 7 of p53 gene in plasma DNA: maybe a new early diagnostic marker of hepatocellular carcinoma in Qidong risk area, China. World J Gastroenterol\u20082003;9:692\u20135.","DOI":"10.3748\/wjg.v9.i4.692"},{"key":"2022061000213242200_BIB26","doi-asserted-by":"crossref","unstructured":"Turner PC, Sylla A, Kuang SY, et al. Absence of TP53 codon 249 mutations in young Guinean children with high aflatoxin exposure. Cancer Epidemiol Biomarkers Prev\u20082005;14:2053\u20135.","DOI":"10.1158\/1055-9965.EPI-04-0923"}],"container-title":["Cancer Epidemiology, Biomarkers &amp; Prevention"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cebp\/article-pdf\/18\/5\/1638\/2269863\/1638.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cebp\/article-pdf\/18\/5\/1638\/2269863\/1638.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T06:13:28Z","timestamp":1654841608000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cebp\/article\/18\/5\/1638\/164721\/TP53-R249S-Mutations-Exposure-to-Aflatoxin-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5,1]]},"references-count":26,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2009,5,7]]},"published-print":{"date-parts":[[2009,5,1]]}},"URL":"https:\/\/doi.org\/10.1158\/1055-9965.epi-08-1102","relation":{},"ISSN":["1055-9965","1538-7755"],"issn-type":[{"value":"1055-9965","type":"print"},{"value":"1538-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,5,1]]}}}